Phase II drugs currently being investigated for the treatment of hypogonadism

Bibliography

• Handelsman DJ. Testosterone physiology. 6 edition. Saunders, Philadelphia, PA; 2010
   Google Scholar
• Bagatell CJ, Bremner WJ. Androgens in men–uses and abuses. N Engl J Med 1996;334:707-14
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59
   PubMed Web of Science ®Google Scholar
• Winters SJ, Clark BJ. Testosterone synthesis, transport, and metabolism. In: Bagatell CJ, Bremner WJ, editors. Androgens in health and disease. Humana Press, New Jersey, USA; 2003. p. 3-22
   Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72
   PubMed Web of Science ®Google Scholar
• Pfeil E, Dobs AS. Current and future testosterone delivery systems for treatment of the hypogonadal male. Expert Opin Drug Deliv 2008;5:471-81
   PubMed Web of Science ®Google Scholar
• Plymate SR. Hypogonadism in men: an overview. In: Bagatell CJ, Bremner WJ, editors. Androgens in health and disease. Humana Press, New Jersey, USA; 2003. p. 45-76
   Google Scholar
• Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56:1278-81
   PubMed Web of Science ®Google Scholar
• Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract 2010;64:682-96
   PubMed Web of Science ®Google Scholar
• Araujo AB, O’Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-6
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31
   PubMed Web of Science ®Google Scholar
• US Census Bureau. National Population Projections. 2008. Available from: http://www.census.gov/population/projections/data/national/2008/summarytables.html [Cited August 2008]
   Google Scholar
• Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241-7
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005;28:125-7
   PubMed Web of Science ®Google Scholar
• Edelstein D, Sivanandy M, Shahani S, et al. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother 2007;8:2991-3008
   PubMed Web of Science ®Google Scholar
• Viswanathan V, Eugster EA. Etiology and treatment of hypogonadism in adolescents. Pediatr Clin North Am 2011;58:1181-200
   PubMed Web of Science ®Google Scholar
• Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl 1989;10:366-71
   PubMed Web of Science ®Google Scholar
• Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981;53:58-68
   PubMed Web of Science ®Google Scholar
• Leifke E, Gorenoi V, Wichers C, et al. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol (Oxf) 2000;53:689-95
   PubMedGoogle Scholar
• Endo Pharmaceuticals. U.S. FDA Approves AVEED™ (Testosterone Undecanoate) Injectable Testosterone Replacement Therapy for Men Living with Hypogonadism, or Low-T. Endo Pharmaeuticals, Inc. Available from: http://www.endo.com/news-events/press-releases Updated March 6, 2014 [Accessed 7 April 2014]
   Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med 2014;11:840-56
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014;68:203-15
   PubMed Web of Science ®Google Scholar
• Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994;15:212-15
   PubMed Web of Science ®Google Scholar
• Kaminetsky JC, Moclair B, Hemani M, et al. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. J Sex Med 2011;8:1186-96
   PubMed Web of Science ®Google Scholar
• McCullough AR, Khera M, Goldstein I, et al. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(R)) insertion. J Sex Med 2012;9:594-601
   PubMed Web of Science ®Google Scholar
• Testopel® [package insert]. Auxilium Pharmaceuticals, Inc, Chesterbrook, PA; 2013
   Google Scholar
• Arver S, Dobs AS, Meikle AW, et al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996;155:1604-8
   PubMed Web of Science ®Google Scholar
• Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997;47:727-37
   PubMed Web of Science ®Google Scholar
• Meikle AW, Arver S, Dobs AS, et al. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. J Clin Endocrinol Metab 1996;81:1832-40
   PubMed Web of Science ®Google Scholar
• AndroGel® 1.62% [package insert]. AbbVie, Inc, North Chicago, IL; 2013
   Google Scholar
• Cutter CB. Compounded percutaneous testosterone gel: use and effects in hypogonadal men. J Am Board Fam Pract 2001;14:22-32
   PubMedGoogle Scholar
• Pope HG Jr, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160:105-11
   PubMed Web of Science ®Google Scholar
• Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-81
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-98
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 2001;54:739-50
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-53
   PubMed Web of Science ®Google Scholar
• Testim® [package insert]. Auxilium Pharmaceuticals, Inc, Chesterbrook, PA; 2013
   Google Scholar
• Coss CC, Jones A, Hancock ML, et al. Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian J Androl 2014;16(2):256-61
   PubMed Web of Science ®Google Scholar
• Zhang X, Sui Z. Deciphering the selective androgen receptor modulators paradigm. Expert Opin Drug Discov 2013;8:191-218
   PubMed Web of Science ®Google Scholar
• de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol 2011;9:93
   PubMed Web of Science ®Google Scholar
• Burnett-Bowie SA, Roupenian KC, Dere ME, et al. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2008. [Epub ahead of print]
   Google Scholar
• Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 2013;8:135-55
   PubMedGoogle Scholar
• Moskovic DJ, Katz DJ, Akhavan A, et al. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int 2012;110:1524-8
   PubMed Web of Science ®Google Scholar
• Bernstein HN. Some iatrogenic ocular diseases from systemically administered drugs. Int Ophthalmol Clin 1970;10:553-619
   PubMedGoogle Scholar
• Christensen RB, Matsumoto AM, Bremner WJ. Idiopathic hypogonadotropic hypogonadism with anosmia (Kallmann’s syndrome). Endocrinologist 1992;2:332-40
   Google Scholar
• Gooren L. Hypogonadotropic hypogonadal men respond less well to androgen substitution treatment than hypergonadotropic hypogonadal men. Arch Sex Behav 1988;17:265-70
   PubMed Web of Science ®Google Scholar
• Johnsen SG. Maintenance of spermatogenesis induced by HMG treatment by means of continuous HCG treatment in hypogonadotrophic men. Acta Endocrinol (Copenh) 1978;89:763-9
   PubMedGoogle Scholar
• Vicari E, Mongioi A, Calogero AE, et al. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism–long-term follow-up. Int J Androl 1992;15:320-9
   PubMed Web of Science ®Google Scholar
• Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002;87:3125-35
   PubMed Web of Science ®Google Scholar
• Aydogdu A, Bolu E, Sonmez A, et al. Effects of three different medications on metabolic parameters and testicular volume in patients with hypogonadotropic hypogonadism: 3-year experience. Clin Endocrinol (Oxf) 2013;79:243-51
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang SX, Dong Q, et al. Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience. Int Urol Nephrol 2012;44:393-9
   PubMed Web of Science ®Google Scholar
• Hsieh TC, Pastuszak AW, Hwang K, et al. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol 2013;189:647-50
   PubMed Web of Science ®Google Scholar
• Miner MM, Sadovsky R. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. Cleve Clin J Med 2007;74(Suppl 3):S38-46
   PubMedGoogle Scholar
• Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999;86:312-15
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007;34:555-63. vii
   PubMed Web of Science ®Google Scholar
• Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014;9:e85805
   PubMed Web of Science ®Google Scholar
• Vigen R, O’Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829-36
   PubMed Web of Science ®Google Scholar
• Antares Pharma. Antares Pharma announces positive results from the Vibex® Quickshot™ pharmacokinetic study in testosterone deficient men. Antares Pharma, Inc. Available from: http://www.antarespharma.com/files/9413/9290/5678/Testosterone_release_final.pdf Updated February 20, 2014 [Accessed 21 February 2014]
   Google Scholar
• Antares Pharma. Form 10-K. Antares Pharma, Inc. 2012. Available from: http://www.antarespharma.com/files/4713/6338/1151/2012_Form_10K.pdf [Cited 17 March 2014]
   Google Scholar
• Lipocine, Inc. LPCN 1021: oral Testosterone Replacement Therapy. Available from: http://www.lipocine.com/LPCN-1021.php [Cited 23 February 2014]
   Google Scholar
• Lipocine, Inc. LPCN 1021 Phase 2 Study. Available from: http://www.lipocine.com/LPCN1021_ph2.php [Cited 23 February 2014]
   Google Scholar
• Lipocine, Inc. LPCN 1021 Phase 3 Study Design. Available from: http://www.lipocine.com/LPCN1021_clinical_info.php [Cited 23 February 2014]
   Google Scholar
• TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug. TesoRx Pharma, LLC. Available from: http://tesorx.com/pdf/TesoRx-CoreRx-Press-release.pdf Updated August 28, 2013 [Accessed 23 February 2014]
   Google Scholar
• TesoRx Pharma, LLC. Oral Testosterone for the Treatment of Hypogonadism. In: ClinicalTrials.gov [Internet]. National Library of Medicine, Bethesda, MD, USA; 2000. Available from: http://clinicaltrials.gov/show/NCT01717768 NLM Identifier: NCT01717768 [Cited 21 February 2014]
   Google Scholar
• TesoRx Pharma, LLC. Product: TSX-002. 2011. Available from: http://tesorx.com/product-tsx.html [Cited 28 March 2014]
   Google Scholar
• Transdermal Delivery Systems Corp. TDSC Receives FDA Approval to Begin Pivotal Clinical Trials of Testagen. TDSC. Available from: http://www.tdsc.us/lower.php?url=press-releases&article=tdsc-gains-fda-approval-for-hrts-test Updated July 30, 2013 [Cited 21 March 2013]
   Google Scholar
• Chik Z, Johnston A, Tucker AT, et al. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br J Clin Pharmacol 2006;61:275-9
   PubMed Web of Science ®Google Scholar
• Chik Z, Johnston A, Tucker AT, et al. Correcting endogenous concentrations of testosterone influences bioequivalence and shows the superiority of TDS(R)-testosterone versus Androgel(R). Int J Clin Pharmacol Ther 2009;47:262-8
   PubMed Web of Science ®Google Scholar
• Transdermal Delivery Solutions Corp.; Barts & The London NHS Trust. A Dose Ranging Study to Examine Testagen™ TDS®-Testosterone 5% (PARC-T-D). In: ClinicalTrials.gov [Internet]. National Library of Medicine, Bethesda, MD, USA; 2000.Available from: http://clinicaltrials.gov/show/NCT01894308 NLM Identifier: NCT01894308 [Cited 21 February 2014]
   Google Scholar
• Banks WA, Morley JE, Niehoff ML, et al. Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone. J Drug Target 2009;17:91-7
   PubMed Web of Science ®Google Scholar
• M et P Pharma. NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers. In: ClinicalTrials.gov [Internet]. National Library of Medicine, Bethesda, MD, USA; 2000. Available from: http://clinicaltrials.gov/show/NCT00647868 NLM Identifier: NCT00647868 [Cited 21 February 2014]
   Google Scholar
• Mattern C, Hoffmann C, Morley JE, et al. Testosterone supplementation for hypogonadal men by the nasal route. Aging Male 2008;11:171-8
   PubMed Web of Science ®Google Scholar
• ASCEND Therapeutics Acquires North American Product Rights for New Product. ASCEND Therapeutics, Inc. Evaluate Group. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=171147&sectionID=&isEPVantage=no Updated June 7, 2004 [Accessed 23 February 2014]
   Google Scholar
• ASCEND Therapeutics. Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80. In: ClinicalTrials.gov [Internet]. National Library of Medicine, Bethesda, MD, USA; 2000. Available from: http://clinicaltrials.gov/show/NCT00163566 NLM Identifier: NCT00163566 [Cited 21 February 2014]
   Google Scholar
• Streuli I, de Ziegler D, Borghese B, et al. New treatment strategies and emerging drugs in endometriosis. Expert Opin Emerg Drugs 2012;17:83-104
   Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men (OHH). In: ClinicalTrials.gov [Internet]. National Library of Medicine, Bethesda, MD, USA; 2000. Available from: http://clinicaltrials.gov/show/NCT01200862 NLM Identifier: NCT01200862 [Cited 21 February 2014]
   Google Scholar
• Cohen PG. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 2008;70:358-60
   Google Scholar
• Raven G, de Jong FH, Kaufman JM, et al. In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab 2006;91:3324-8
   PubMed Web of Science ®Google Scholar
• T’Sjoen GG, Giagulli VA, Delva H, et al. Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab 2005;90:5717-22
   PubMed Web of Science ®Google Scholar
• Hill S, Arutchelvam V, Quinton R. Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. IDrugs 2009;12:109-19
   PubMedGoogle Scholar
• Repros Therapeutics, Inc. Exploratory Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus and Secondary Hypogonadism or Adult-Onset Idiopathic Hypogonadotropic Hypogonadism. In: ClinicalTrials.gov [Internet]. National Library of Medicine, Bethesda, MD, USA; 2000. Available from: http://clinicaltrials.gov/show/NCT01191320 NLM Identifier: NCT01191320 [Cited 21 February 2014]
   Google Scholar
• Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. BJU Int 2013;112:1188-200
   Web of Science ®Google Scholar
• Corona G, Vignozzi L, Sforza A, et al. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health 2013;31:103-25
   PubMedGoogle Scholar
• Seftel A. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 2007;19:2-24
   PubMed Web of Science ®Google Scholar
• Saad F, Gooren LJ, Haider A, et al. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008;29:102-5
   PubMed Web of Science ®Google Scholar
• Yassin DJ, Doros G, Hammerer PG, et al. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014;11:1567-76
   PubMed Web of Science ®Google Scholar
• FDA. FDA Drug Safety Communication: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. 2014. Available from: http://www.fda.gov/drugs/drugsafety/ucm383904.htm Updated January 31, 2014 [Cited 23 February 2014]
   Google Scholar
• Twenty-Five Medical Societies Join Androgen Study Group to Petition JAMA to Retract Misleading Testosterone Study. PR Newswire, Boston, MA; April 10 2014. Available from: http://www.prnewswire.com/news-releases/twenty-five-medical-societies-join-androgen-study-group-to-petition-jama-to-retract-misleading-testosterone-study-254707661.html [Accessed 13 April 2014]
   Google Scholar
• Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009;94:2353-9
   PubMed Web of Science ®Google Scholar
• Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 2011;58:1674-81
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Mootha VK, Dwyer AA, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005;28:1636-42
   PubMed Web of Science ®Google Scholar
• Makhsida N, Shah J, Yan G, et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005;174:827-34
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169:725-33
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Vignozzi L, et al. Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs 2012;17:239-59
   PubMed Web of Science ®Google Scholar
• Ruige JB, Ouwens DM, Kaufman JM. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab 2013;98:4300-10
   PubMed Web of Science ®Google Scholar
• University of Pennsylvania; National Institute on Aging; National Institute of Neurological Disorders and Stroke; National Institute of Child Health and Human Development; National Heart, Lung, and Blood Institute; Abbott. The Testosterone Trial in Older Men. In: ClinicalTrials.gov [Internet]. National Library of Medicine, Bethesda, MD, USA; 2000. Available from: http://clinicaltrials.gov/show/NCT00799617 NLM Identifier: NCT00799617 [cited 14 April 2014]
   Google Scholar
• Shortridge EF, Polzer P, Donga P, et al. Experiences and treatment patterns of hypogonadal men in a U.S. health system. Int J Clin Pract 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Antares Pharma, Inc. Pharmacokinetic Study of Testosterone Enanthate. In: ClinicalTrials.gov [Internet]. National Library of Medicine, Bethesda, MD, USA; 2000. Available from: http://clinicaltrials.gov/show/NCT01887418 NLM Identifier: NCT01887418 [Cited 21 February 2014]
   Google Scholar
• Natesto™ [package insert]. Trimel Pharmaceuticals Corp, Mississauga, ON; 2014
   Google Scholar
• Andriol® [package insert]. Merck Canada, Inc; Kirkland, QC: 2011
   Google Scholar